<DOC>
	<DOCNO>NCT02252263</DOCNO>
	<brief_summary>To assess safety tolerability , characterize dose limit toxicity ( DLTs ) identify maximally tolerate dose ( MTD ) Elotuzumab administer combination either Lirilumab Urelumab subject multiple myeloma .</brief_summary>
	<brief_title>A Phase I Open Label Study Safety Tolerability Elotuzumab ( BMS-901608 ) Administered Combination With Either Lirilumab ( BMS-986015 ) Urelumab ( BMS-663513 ) Subjects With Multiple Myeloma</brief_title>
	<detailed_description>Allocation : - Part1 : Non-randomized - Part2 : Randomized</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Subjects must histological confirmation multiple myeloma measurable disease ( per International Myeloma Working Group ( IMWG ) criterion ) : Relapsed/refractory multiple myeloma , subject post autologous transplant achieve good partial response ( VGPR ) complete response ( nCR ) minimal residual disease ( MRD )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>